Kazia Therapeutics在晚期转移性三阴性乳腺癌Paxalisib一期B阶段研究中报告积极初步临床反应

美股速递
Jan 27

Kazia Therapeutics Limited(简称:Kazia)在其针对晚期转移性三阴性乳腺癌患者开展的Paxalisib药物一期B阶段临床研究中,公布了令人鼓舞的初步临床反应数据。该研究目前仍在进行中,最新结果显示Paxalisib在治疗这一难治型癌症方面展现出潜在疗效。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10